GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Debt-to-Revenue

VGI Health Technology (XNEC:VTL) Debt-to-Revenue : 0.00 (As of . 20)


View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

VGI Health Technology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was A$0.00 Mil. VGI Health Technology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was A$0.00 Mil. VGI Health Technology's annualized Revenue for the quarter that ended in . 20 was A$0.00 Mil.

VGI Health Technology Debt-to-Revenue Historical Data

The historical data trend for VGI Health Technology's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Debt-to-Revenue Chart

VGI Health Technology Annual Data
Trend
Debt-to-Revenue

VGI Health Technology Semi-Annual Data
Debt-to-Revenue

Competitive Comparison of VGI Health Technology's Debt-to-Revenue

For the Biotechnology subindustry, VGI Health Technology's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VGI Health Technology's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VGI Health Technology's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where VGI Health Technology's Debt-to-Revenue falls into.


VGI Health Technology Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

VGI Health Technology's Debt-to-Revenue for the fiscal year that ended in . 20 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=( + ) / N/A
=N/A

VGI Health Technology's annualized Debt-to-Revenue for the quarter that ended in . 20 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=( + ) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is one times the quarterly (. 20) Revenue data.

VGI Health Technology Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

VGI Health Technology (XNEC:VTL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Debt-to-Revenue
Comparable Companies
Traded in Other Exchanges
N/A
Address
19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003
Website
https://www.vgiht.com
VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines